Core Points - The document provides information regarding the total number of voting rights and shares for Sanofi as of October 31, 2025 [1] - Sanofi has a registered share capital of €2,454,937,946 and is registered at the Paris Commercial and Companies Registry [1] Summary by Category Total Number of Shares and Voting Rights - The total number of issued shares is 1,227,469,992 [1] - The theoretical number of voting rights, excluding treasury shares, is 1,348,747,993 [1] - The theoretical number of voting rights, including treasury shares, is 1,361,720,228 [1] Regulatory Compliance - The information is provided in accordance with article L. 233-8 II of the French Commercial Code and article 223-16 of the Regulation of the French stock market authority [1] - Additional information is available on Sanofi's official website under "Regulated Information in France" [2]

Core Viewpoint - Openbank, Santander's digital lender, has launched a cryptocurrency trading service in Spain, following the lead of rival BBVA [1] Company Summary - Openbank is expanding its service offerings by introducing cryptocurrency trading, indicating a strategic move to enhance its digital banking capabilities [1] - The launch of this service positions Openbank competitively within the growing digital finance sector, particularly in the cryptocurrency market [1] Industry Summary - The cryptocurrency trading service launch reflects a broader trend among banks in Spain to embrace digital assets, highlighting the increasing acceptance of cryptocurrencies in traditional banking [1] - The move by Openbank and BBVA signifies a shift in the banking industry towards integrating cryptocurrency services, potentially attracting a new customer base interested in digital currencies [1]

Core Insights - The article discusses the current market concentration, particularly focusing on the performance of the "Mag 7" stocks compared to the broader S&P 493, highlighting a significant bifurcation in earnings and profit margins [2][3][5] - It emphasizes the importance of diversification in investment strategies, noting that investing solely in the Mag 7 stocks does not provide adequate diversification within the S&P 500 [5] Market Analysis - Torsten Slok, chief economist at Apollo Global Management, noted that the 2025 EPS consensus estimates for the Mag 7 have increased, while those for the S&P 493 have decreased, indicating a concentration of earnings growth in the Mag 7 [2][3] - The Mag 7 stocks now account for over 40% of the total market capitalization of the S&P 500, which is considered an unusually high concentration [4] Investment Strategy - The article presents a list of the 14 best undervalued stocks to buy under $50, selected based on a forward P/E ratio below 15 and the number of hedge fund holders [7] - The methodology for selection is based on hedge fund sentiment, with the aim of outperforming the market by following top stock picks from leading hedge funds [8] Company Highlights - **Banco Santander, S.A. (NYSE:SAN)**: - Stock Price: $10.29, Forward P/E: 10.40, Hedge Fund Holders: 18 - Reported stable revenue of €46.3 billion and a record net fee income, up 4% year-over-year [11] - Attributable profit for the first nine months of 2025 reached €10.337 billion, an 11% increase from the previous year [12] - Added over seven million new customers, bringing the total to 178 million [13] - **Equinor ASA (NYSE:EQNR)**: - Stock Price: $24.04, Forward P/E: 8.68, Hedge Fund Holders: 19 - Received a Hold rating with a price target of $22 [15] - Awarded new framework agreements valued at approximately NOK 17 billion for insulation and scaffolding services at its onshore plants in Norway [17]

Core Insights - The latest investment trends show that top mutual funds are increasingly investing in AI-related stocks, with Nvidia and Palantir joining the ranks of major companies like Alphabet and Apple [8][10]. Investment Highlights - Banco Santander led the list with a significant investment of $16.12 billion, followed by Ormat Technologies at $14.31 billion, AAR Corp at $8.89 billion, and Nextracker at $1.96 billion [2][4][6]. - Ormat Technologies has seen its stock price rise significantly, nearing an all-time high due to strong demand from mutual funds [4]. - AAR Corp is also performing well, with a capital inflow of $8.89 billion, and is currently testing its 50-day moving average [5]. - Nextracker, after a slump post-IPO, has rebounded with a $1.96 billion investment, reaching a record high before recent market pressures [5]. Additional Notable Investments - Other companies that attracted substantial investments include Celestica with $734 million, Seagate Technology with $669 million, GSK with $288 million, and TE Connectivity with $202 million [7]. - Despite lower investment amounts compared to previous months, Nvidia, Palantir, Alphabet, and Apple still made the list of new buys, indicating continued interest in these tech giants [8][10]. - IBM has also emerged as a strong investment choice, with its stock performing well following a positive earnings report [11].

Core Insights - The pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent (dupilumab) showed significant improvements in allergic fungal rhinosinusitis (AFRS) symptoms, meeting all primary and secondary endpoints [1][5][6] - The FDA has accepted the supplemental biologics license application (sBLA) for Dupixent in treating AFRS, which could become its ninth approved indication [2][5] Study Results - The study demonstrated a 50.0% improvement in sinus opacification scores for Dupixent compared to 9.8% for placebo at 52 weeks, with a significant reduction observed at 24 weeks [6] - Patient-reported nasal congestion improved by 66.7% at 24 weeks and 80.6% at 52 weeks in the Dupixent group compared to 25.3% and 11.1% in the placebo group, respectively [6][13] - Nasal polyp size reduced by 60.8% at 24 weeks and 62.5% at 52 weeks in the Dupixent group compared to 15.2% and 3.6% in the placebo group [13] Safety Profile - The overall rates of adverse events were 70% for Dupixent and 79% for placebo, with serious adverse events reported in 0% of Dupixent patients compared to 7% for placebo [7] - Common treatment-emergent adverse events included COVID-19 and nosebleeds, with similar rates between Dupixent and placebo [7] Background on AFRS - AFRS is a chronic type 2 inflammatory disease of the sinuses caused by allergic hypersensitivity to fungi, primarily affecting individuals in warm, humid climates [3][5] - Current treatment options are limited, often involving surgery and prolonged systemic steroids, with a high rate of disease recurrence [3][4] Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits IL4 and IL13 signaling pathways, showing significant clinical benefits in various type 2 inflammatory diseases [10][11] - The drug has received regulatory approvals in over 60 countries for multiple indications, with more than one million patients treated globally [11][12]

Nov 6, 2025 10:00 AM Eastern Standard Time Santander Bank Launches Navigator Global to Empower U.S. Businesses Expanding Internationally Share New digital platform provides small and mid-sized enterprises with tools, insights, and connections to grow in global markets. NEW YORK--(BUSINESS WIRE)--Santander Bank, N.A. announced today the launch of Navigator Global, a new digital platform designed to help small and mid-sized U.S. businesses explore, enter, and expand into international markets. The platform le ...

Core Insights - Spanish lender Santander is preparing to appoint an insider as the next UK chief executive, indicating a preference for internal candidates [1] - The shortlisted candidates include Mahesh Aditya, the group chief risk officer, and Enrique Alvarez Labiano, the head of UK retail and business banking [1]

Core Insights - Santander has launched a new platform, Navigator Global, aimed at assisting businesses in expanding internationally by connecting them with verified providers, local experts, and real-time insights [2][4] - The platform is designed to reduce risks associated with global trade and offers guidance for businesses looking to export or enter new markets [2][4] - The updated platform builds on a previous version that supported over 2,500 businesses in the UK and is now available in more than 40 markets [3] Industry Context - Research indicates that 65% of goods firms have experienced operational disruptions due to uncertainty, with this figure rising to 83% among companies facing high regulatory changes [5] - The evolving regulatory frameworks and compliance obligations are complicating risk management for firms, as they deal with both rising input costs and shifting rules [6] - Companies that perform well are effectively managing uncertainty by investing in scenario planning, adjusting cash flow forecasts monthly, and diversifying logistics providers [7]

Core Viewpoint - The executive chair of Spain's Santander, Ana Botin, cautioned against overregulation in Europe, highlighting it as a potential risk that could negatively impact economic growth on the continent [1] Group 1 - Ana Botin emphasized the importance of avoiding excessive regulatory measures in Europe [1] - The warning reflects concerns about the balance between regulation and economic growth [1] - The statement indicates a broader industry sentiment regarding the implications of regulatory frameworks on financial institutions [1]

Core Viewpoint - Banco Santander maintains a positive outlook despite recent challenges in the UK market, with an "Overweight" rating and an increased price target from EUR 9.50 to EUR 10 by Morgan Stanley [2][6]. Company Performance - In the recent quarter, Santander UK experienced a net loss of 23,000 accounts, attributed to over 33,000 account closures and just over 10,000 new accounts opened [3][6]. - The current stock price of SAN on the NYSE is $10.28, reflecting a slight decrease of 0.72% with a change of $0.075 [3]. - The stock has shown volatility, with a daily trading range between $10.13 and $10.33, and over the past year, it reached a high of $10.50 and a low of $4.43 [4]. Market Position - Banco Santander's market capitalization is approximately $152.79 billion, with a trading volume of 2,632,778 shares, indicating strong investor interest [4][6]. - While Santander UK faced account losses, competitors like Nationwide Building Society and the Co-operative Bank gained customers, highlighting a shift in consumer preferences [5].